Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Risk Disclosure In Drug Ads Will Be FDA’s Focus After House Defeats DTC Ban

Jun 25 2007

• By Carlene Olsen

Related Content

FDA DIRECT-TO-CONSUMER BROADCAST GUIDANCE TO BE EVALUATED AFTER TWO YEARS; "ADEQUATE PROVISION" OF LABELING POSSIBLE THROUGH FOUR-PART APPROACH

Aug 11 1997

FDA, Industry Assess Best Way To Communicate Risk in DTC Ads

Jun 25 2007

Amylin Agrees To Symlin Marketing Restrictions In Gaining FDA Approval

Mar 21 2005

Drug Advertising’s Shift To The Web Will Be Sped By Better Metrics – Merck

May 15 2006

DTC Limits Best Countered By Free Speech, Not Public Health, Arguments

Apr 16 2007

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window